TP53 and head and neck squamous cell carcinoma: As proof of concept, we developed a TP53-specific CyclomicsSeq protocol and a dedicated software pipeline to determine the mutation burden of a series of cfDNA samples obtained from liquid biopsies from patients with Human Papilloma Virus (HPV) negative head-and-neck squamous cell carcinoma (HNSCC).